New hope for myeloma patients: switching to ixazomib after failed treatments?

NCT ID NCT05013190

Ongoing Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 72 adults with multiple myeloma who switch from a bortezomib- or carfilzomib-based treatment to an ixazomib-based regimen. Researchers are tracking side effects and how long patients go without the disease getting worse. The goal is to see if this switch is a good option in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ixazomib (NINLARO®)
What this could lead to: If successful, this study could show that switching to ixazomib is a safe and effective option for multiple myeloma patients who have already tried bortezomib or carfilzomib.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove cause and effect. It is also small (72 participants) and focused on Chinese patients, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, 010050, China
Anhui Cancer Hospital

Hefei, Anhui, 230000, China
Beijing Chao-Yang Hospital,Capital Medical University

Beijing, Beijing Municipality, 100020, China
Beijing Jishuitan Hospital

Beijing, Beijing Municipality, 100096, China
Henan Province People Hospital

Zhengzhou, Henan, 450004, China
Qingdao Municipal Hospital

Qingdao, Qingdao, 266071, China
Shengjing Hospital affiliated to China Medical University

Shenyang, Liaoning, 110022, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Zhenzhou University

Zhengzhou, Henan, 450052, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.